// App-Quantinova.ai

3216 : Anti-PD-1, Anti-PD-L1 and Anti-CTLA-4 checkpoint inhibitor treatment leads to different responses in syngeneic tumor models

Researchers

Presenter

  • Peter Jantscheff

Principal Investigators

  • Cynthia Schaefer-Obodozie

  • Sandra Moor

  • Holger Weber

Medical Centers

  • ProQinase GmbH, Freiburg, Germany

Locations

  • Germany

Companies

  • ProQinase GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved